Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Clinicopathological features and prognosis analysis of 11 patients with TFE3-rearranged perivascular epithelioid cell tumors.

Yin-Miao Bai, Li Yang, Yingchen Shi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23551

e23551 Background: To explore the clinicopathological features and prognostic analysis of TFE3...

Comparative outcomes of FLAG-based versus standard 3+7 induction therapy in adults with newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis.

Mohammed Abdulgayoom, Soha Aboukhalaf, Mahmoud Osman et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18518

e18518 Background: Standard induction therapy for fit adults with newly diagnosed acute myeloid leukemia (AML) remains dau...

Neuropsychiatric symptom and biomarker changes with electroacupuncture in adolescent and young adult (AYA) cancer survivors: Results from a randomized controlled trial.

Alexandre Chan, Matthew Heshmatipour, Ding Quan Ng et al. Jun 01, 2026 pp. 10054-10054 10.1200/jco.2026.44.16_suppl.10054

10054 Background: Electroacupuncture (EA) shows promise for managing neuropsychiatric symptoms, yet its role in adolescent...

An academic multimodal ctDNA strategy for minimal residual disease detection and therapy monitoring in advanced epithelial ovarian cancer: Insights from the phase IV IOLANTHE trial.

Lara Paracchini, Thu Hoai Dang, Laura Mannarino et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17547

e17547 Background: Sensitive detection of minimal residual disease (MRD) and longitudinal monitoring of treatment response...

Clinical benefit of oral selective estrogen receptor degraders in <i>ESR1</i> -mutant, HR-positive, HER2-negative advanced breast cancer: A systematic review and meta-analysis.

Natalia Nunes, Lorrany Larisse Costa Rodrigues, Lara De Holanda Jucá Silveira et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13058

e13058 Background: ESR1 mutations are a key mechanism of acquired endocrine resistance in hormone receptor-positive, HER2-...

Real-world outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer with central nervous system metastases: A multicenter cohort from Poland, the Czech Republic, and Slovakia.

Malgorzata Pieniazek, Milos Holanek, Katarzyna Świderska et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13120

e13120 Background: Patients with metastatic triple-negative breast cancer (mTNBC) and central nervous system (CNS) metasta...

Trends of occupational cancer notification in Brazil (2010-2024): A 15-year national database analysis.

Jessica Ribeiro Gomes, Hanna Kim Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23354

e23354 Background: Occupational cancer is a significant yet under-recognized public health issue. While work-related expos...

Trends and patterns of lung cancer among psychoactive substance–using older adults in the United States 1999-2024: A CDC WONDER analysis.

Fareed Baksh, Fnu Hafeezullah, Areesha Nawaz et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20086

e20086 Background: Lung cancer remains a leading cause of cancer-related morbidity and mortality in the United States. Cig...

Survival outcomes with first-line platinum–etoposide plus durvalumab versus platinum–etoposide alone in extensive-stage small cell lung cancer with metastatic disease including brain metastases: A real world analysis.

Ghulam Shah, Katherin Zambrano, Antonio Arciniegas Rubio et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20138

e20138 Background: Patients with extensive-stage small cell lung cancer (ES-SCLC) frequently present with metastatic disea...

Circulating heat shock protein 90 alpha (Hsp90α) as a biomarker for cancer cachexia.

Syed Hasan Raza Jafri, Edson Alves de Lima Junior, Julie Haewon Rowe et al. Jun 01, 2026 pp. 12042-12042 10.1200/jco.2026.44.16_suppl.12042

12042 Background: Cancer cachexia is defined clinically by a consensus definition of ≥5% unintentional weight loss in canc...

SEZanne: A phase 2 randomized, open-label, multicenter study to evaluate the optimal dose, safety, and efficacy of ABBV-706 in combination with atezolizumab (atezo) versus standard of care (SOC) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC).

Kristof Cuppens, Lauren Averett Byers, Yasushi Goto et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps8135

TPS8135 Background: SCLC is a neuroendocrine tumor accounting for ~15% of lung cancers, with a 5-year survival rate of ~7%...

Sex-dependent features of primary non-small cell lung cancer course in patients with previous COVID-19.

Galina V. Zhukova, Elena M. Frantsiyants, Alla Ivanovna Shikhlyarova et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20044

e20044 Background: According to global statistics, women generally experience a milder response to COVID-19 than men, and...

The ATLAS study: A first-in-human phase 1/2 trial of [Ac-225]RTX-2358 in patients with relapsed or refractory soft tissue sarcoma.

Sandra P. D'Angelo, William D. Tap, Ankit Mangla et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps11598

TPS11598 Background: Fibroblast Activation Protein (FAP) is expressed on the surface of cancer-associated fibroblasts and...

Preliminary results of a phase II study to evaluate the efficacy and safety of disitamab vedotin (RC48-ADC) in combination with radiotherapy for adjuvant therapy in upper tract urothelial carcinoma.

Zihao Tao, Chunru Xu, Xiaoying Li et al. Jun 01, 2026 pp. 4605-4605 10.1200/jco.2026.44.16_suppl.4605

4605 Background: Although postoperative platinum-based adjuvant chemotherapy improves disease-free survival (DFS), many up...

Early outpatient palliative care for patients with multiple myeloma: A randomized pilot study.

Breffni Hannon, Samantha Lo, Criselda Isabel Cenizal et al. Jun 01, 2026 pp. 12051-12051 10.1200/jco.2026.44.16_suppl.12051

12051 Background: Early palliative care is recommended for patients with advanced or incurable cancer. Despite these recom...

Automated identification of phenotypically aberrant cells in acute myeloid leukemia MRD: An unsupervised machine learning approach.

Ansh Kumar, Jake Silberg, Meindert Niemeijer et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18560

e18560 Background: Measurable residual disease (MRD) serves as a robust prognostic marker in acute myeloid leukemia (AML),...

DISCO app: Feasibility and acceptability of an intervention to reduce the financial burden of cancer in a diverse patient population.

Lauren M. Hamel, David W. Dougherty, Seongho Kim et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13729

e13729 Background: Financial toxicity, the burden of treatment cost, affects up to half of people with cancer and can affe...

Prospective evaluation of the pan-immune-inflammation value (PIV) as an independent prognostic biomarker in EGFR-mutated advanced non-small cell lung cancer.

Deepa Aggarwal, Kadabur Nagendrappa Lokesh Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20512

e20512 Background: EGFR mutations are frequent in Non-Small Cell Lung Cancer (NSCLC), with an estimated prevalence of 38.8...

Characterizing patient self-reported adherence to BTKis and symptoms in CLL/SLL using an electronic patient-reported outcomes (ePRO) platform.

Mustafa Ascha, Ronda Copher, Lee Ding et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19030

e19030 Background: The covalent Bruton tyrosine kinase inhibitors (BTKis) zanubrutinib and acalabrutinib have revolutioniz...

A digital educational and decision-support intervention for patients with advanced lung cancer receiving immunotherapy: Results of a multi-phase, mixed-methods study.

Matthias Villalobos, Phoebe Ullrich, Henrike Voss et al. Jun 01, 2026 pp. 12094-12094 10.1200/jco.2026.44.16_suppl.12094

12094 Background: Immunotherapy has transformed the treatment of advanced lung cancer, but it has also increased the compl...

GLP-1 RA for primary prevention of post-mastectomy lymphedema in breast cancer patients: A multicenter real-world analysis.

Dawit Hailemariam Yesho, Muluken Megiso, Chidiebube Ugwu et al. Jun 01, 2026 pp. 628-628 10.1200/jco.2026.44.16_suppl.628

628 Background: Post-mastectomy lymphedema (PML) remains a significant morbidity for breast cancer (BC) survivors, particu...

Association of iterative cannabis care plans with rates of symptom relief and side effect burden in oncology patients.

Brooke Worster, Kristen Parton, Gregory D. Garber Jun 01, 2026 pp. 12070-12070 10.1200/jco.2026.44.16_suppl.12070

12070 Background: Cannabis is increasingly used to manage cancer-related symptoms including pain, sleep disturbance, anxie...

Presenting and therapy-related psychiatric manifestations of metastatic and primary brain tumors: A meta-analysis and systematic review.

Samuel Kim, Joel Setya, Rishabh Gaur et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14080

e14080 Background: Brain tumors range widely in histopathological characteristics and clinical severity. Presenting clinic...

Sex-based differences in in-hospital outcomes among hospitalized patients with lung cancer receiving immunotherapy: A National Inpatient Sample study.

Alice He, Tony Elias, Christopher G. Cann Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23073

e23073 Background: Lung cancer is the second most common malignancy and the leading cause of cancer-related mortality in t...

Fragmentia AI–Lymphoma: A cfDNA language model for lymphoma detection using ultra-low-pass WGS.

Rui Liu, Yang Dai, Xushu Zhong et al. Jun 01, 2026 pp. 7019-7019 10.1200/jco.2026.44.16_suppl.7019

7019 Background: Despite the potential of cfDNA liquid biopsy for non-invasive cancer monitoring, its clinical utility is...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page